A study exploring critical pathways in clear cell renal cell carcinoma

被引:13
作者
Zeng, Zisan [1 ]
Que, Tengcheng [2 ]
Zhang, Jiange [3 ]
Hu, Yanling [4 ,5 ]
机构
[1] Guangxi Med Univ, Affiliated Hosp 1, Dept Radiol, Nanning 530021, Guangxi, Peoples R China
[2] Forestry Bur Guangxi, Wild Anim Rescue Ctr, Nanning 530021, Guangxi, Peoples R China
[3] Guangxi Med Univ, Affiliated Hosp 1, Dept Urol, Nanning 530021, Guangxi, Peoples R China
[4] Guangxi Med Univ, Med Sci Res Ctr, Nanning 530021, Guangxi, Peoples R China
[5] Guangxi Med Univ, Nanning 530021, Guangxi, Peoples R China
基金
中国国家自然科学基金;
关键词
clear cell renal cell carcinoma; pathway analysis; meta-analyis; gene expression; SET ENRICHMENT ANALYSIS; TRANS-RETINOIC ACID; 13-CIS-RETINOIC ACID; INTERFERON ALPHA-2A; HEREDITARY LEIOMYOMATOSIS; PHASE-II; EXPRESSION; GENE; CANCER; TRIAL;
D O I
10.3892/etm.2013.1392
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Renal cell carcinoma (RCC) is the most lethal type of cancer in the urinary system and often presents as a metastatic disease. Furthermore, there are no effective treatments for the disease. Several studies based on gene expression profiling have been performed with the aim of gaining insights into the pathogenesis of RCC; however, few studies have investigated RCC at the pathway level to search for the possible pathways involved in clear cell RCC (CCRCC). In this study, gene set enrichment analysis (GSEA) was conducted on microarray datasets from CCRCC tissue. DAVID functional enrichment analysis was performed based on the dysregulated genes that were identified in a meta-analysis performed on the microarray datasets from CCRCC tissue. In GSEA, 17 down- and 12 upregulated pathways coexisted in six datasets. The majority of the upregulated pathways were associated with the immune system. In addition, 32 dysregulated pathways were obtained from DAVID functional enrichment analysis, based on the abnormal genes identified by meta-analysis. This study demonstrated that cross-GSEA is a useful method for exploring the critical pathways involved CCRCC; however, an individual dataset with a small sample may introduce bias. A cross-GSEA based on certain well-designed datasets may be required to further the progress made in this study, following the analysis of its results.
引用
收藏
页码:121 / 130
页数:10
相关论文
共 60 条
  • [31] Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: A novel method to potentiate natural killer cell tumor cytotoxicity
    Lundqvist, Andreas
    Abrams, Scott I.
    Schrump, David S.
    Alvarez, Gauri
    Suffredini, Dante
    Berg, Maria
    Childs, Richard
    [J]. CANCER RESEARCH, 2006, 66 (14) : 7317 - 7325
  • [32] Group testing for pathway analysis improves comparability of different microarray datasets
    Manoli, Theodora
    Gretz, Norbert
    Grone, Hermann-Josef
    Kenzelmann, Marc
    Eils, Roland
    Brors, Benedikt
    [J]. BIOINFORMATICS, 2006, 22 (20) : 2500 - 2506
  • [33] Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management
    Maruschke, Matthias
    Reuter, D.
    Koczan, D.
    Hakenberg, O. W.
    Thiesen, H. -J.
    [J]. BJU INTERNATIONAL, 2011, 108 (2B) : E29 - E35
  • [34] Molecular architecture of tight junctions
    Mitic, LL
    Anderson, JM
    [J]. ANNUAL REVIEW OF PHYSIOLOGY, 1998, 60 : 121 - 142
  • [35] PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
    Mootha, VK
    Lindgren, CM
    Eriksson, KF
    Subramanian, A
    Sihag, S
    Lehar, J
    Puigserver, P
    Carlsson, E
    Ridderstråle, M
    Laurila, E
    Houstis, N
    Daly, MJ
    Patterson, N
    Mesirov, JP
    Golub, TR
    Tamayo, P
    Spiegelman, B
    Lander, ES
    Hirschhorn, JN
    Altshuler, D
    Groop, LC
    [J]. NATURE GENETICS, 2003, 34 (03) : 267 - 273
  • [36] Claudin proteins in human cancer: Promising new targets for diagnosis and therapy
    Morin, PJ
    [J]. CANCER RESEARCH, 2005, 65 (21) : 9603 - 9606
  • [37] INTERFERON ALFA-2A AND 13-CIS-RETINOIC ACID IN RENAL-CELL CARCINOMA - ANTITUMOR-ACTIVITY IN A PHASE-II TRIAL AND INTERACTIONS IN-VITRO
    MOTZER, RJ
    SCHWARTZ, L
    LAW, TM
    MURPHY, BA
    HOFFMAN, AD
    ALBINO, AP
    VLAMIS, V
    NANUS, DM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) : 1950 - 1957
  • [38] Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma
    Motzer, RJ
    Murphy, BA
    Bacik, J
    Schwartz, LH
    Nanus, DM
    Mariani, T
    Loehrer, P
    Wilding, G
    Fairclough, DL
    Cella, D
    Mazumdar, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) : 2972 - 2980
  • [39] Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinoma
    Recchia, Francesco
    Saggio, Gaetano
    Amiconi, Giovanna
    Di Blasio, Anna
    Cesta, Alisia
    Candeloro, Giampiero
    Necozione, Stefano
    Fumagalli, Luca
    Rea, Silvio
    [J]. JOURNAL OF IMMUNOTHERAPY, 2007, 30 (04) : 448 - 454
  • [40] Chemokines as therapeutic targets in renal cell carcinoma
    Reckamp, Karen L.
    Strieter, Robert M.
    Figlin, Robert A.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (06) : 887 - 893